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Abstract
In recent years, efforts to eliminate malaria has gained a tremendous 
 momentum, and many countries have achieved this goal — but it has faced many 
challenges. Recent COVID-19 pandemic has compounded the challenges due to 
cessation of many on-field operations. Accordingly, the World Health Organization 
(WHO) has advocated to all malaria-endemic countries to continue the malaria 
elimination operations following the renewed protocols. The recent reports of arte-
misinin resistance in Plasmodium falciparum followed by indication of chloroquine 
resistance in P. vivax, and reduced susceptibility of synthetic pyrethroids used 
in long lasting insecticide nets are some issues hindering the elimination efforts. 
Moreover, long distance night migration of vector mosquitoes in sub-Saharan Africa 
and invasion of Asian vector Anopheles stephensi in many countries including Africa 
and Southeast Asia have added to the problems. In addition, deletion of histidine 
rich protein 2 and 3 (Pfhrp2/3) genes in P. falciparum in many countries has opened 
new vistas to be addressed for point-of-care diagnosis of this parasite. It is needed 
to revisit the strategies adopted by those countries have made malaria elimination 
possible even in difficult situations. Strengthening surveillance and larval source 
management are the main strategies for successful elimination of malaria. New 
technologies like Aptamar, and artificial intelligence and machine learning would 
prove very useful in addressing many ongoing issues related to malaria elimination.
Keywords: Malaria, Plasmodium vivax, P. falciparum, drug resistance,  
vector invasion, night migration, insecticide resistance, gene deletions,  
surveillance, larval source management, elimination, Aptamar, Artificial intelligence, 
machine learning, COVID-19
1. Introduction
In the past two decades, tremendous progress has been made in the fight against 
malaria. A great deal of new knowledge on malaria parasite [1], insights in vec-
tor biology and control have helped target interventions resulting in substantial 
transmission reduction globally [2–4]. In 2019, World Health Organization (WHO) 
estimated 229 million malaria cases and 409,000 deaths in 87 malaria-endemic coun-
tries with large concentration of the total malaria burden (94%) in Africa [5]. Global 
malaria cases declined by 27% between 2000 and 2015, and only 2% between 2015 
and 2019 indicating the slow progress rate in this period (Figure 1) [5]. Of the 29 
countries that contributed 95% of the global malaria cases, Nigeria alone accounted 
for the highest at 27% followed by Democratic Republic of the Congo (12%), Uganda 
(5%), Mozambique (4%) and Niger (3%). A compiled data of global malaria cases 
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from 2000 to 2019 showed a declining trend (Figure 1). But the trend between 2015 
and 2019 is not a good indication of malaria elimination goal from 2016 to 2030, as 
envisaged by the Global Technical Strategy (GTS) of WHO. The population at risk 
living in the WHO African Region increased from about 665 million in 2000 to 1.1 
billion in 2019. The WHO South-East Asia Region (SEAR) accounted for about 3% 
of the burden of malaria cases globally. India is the major contributor in this region 
sharing 2% of the total global malaria cases. On the other hand, seven countries 
namely Algeria, Kyrgyzstan, Uzbekistan, Argentina, Paraguay, Maldives and Sri 
Lanka have been certified malaria free by WHO from 2015 to 2019 [6]. Among the 
E-2020 countries: China, Iran, Timor-Leste, Malaysia and El-Salvador reported zero 
malaria in 2018 setting a precedent that malaria elimination is possible by strength-
ening surveillance system (Figure 2) [7]. In 2020, the whole world experienced an 
unprecedented situation of COVID-19 pandemic threatening malaria elimination 
efforts. Most of the public health services were diverted towards managing and 
containing this severe form of infection caused by SARS-COV-2 virus. Aims and aspi-
rations are high for living in the malaria-free world, yet there are multiple challenges 
for realizing the goal of malaria elimination by 2030. Enumerated below are some of 
Figure 1. 
Trends of global malaria 2000 to 2019. Nigeria alone continue to contribute majority of the cases; in 2019 
contributed 27% of total global malaria cases. Compiled from WHO data.
Figure 2. 
Global malaria burden. Countries with indigenous cases in 2000 and their status by 2019. Source WHO [5].
3
New Challenges in Malaria Elimination
DOI: http://dx.doi.org/10.5772/intechopen.96532
issues which should be addressed to strengthen the health systems for the achieving 
coveted goal of malaria elimination in due time.
2. Search methods
Searched MEDLINE (PubMed); CABS Abstracts; checked the reference lists of 
all studies identified by the search. Also performed Google Search on specific topics. 
Examined references listed in review articles and previously compiled bibliographies.
3. The challenges
Besides the current impending threat of COVID-19, many more challenges are 
being faced in defeating malaria. Some of these are: (a) deletions of PfHPR2/3 
genes in Plasmodium falciparum at the point-of-care diagnosis, (b) drug resistance 
to parasites, (c) migration of parasite strains to newer areas, (d) migration of drug-
resistant parasites in low-transmission settings, (e) multi-insecticide resistance in 
vector mosquitoes, (f) poor disease surveillance, (g) invasion of Anopheles stephensi 
in Africa and elsewhere, (h) long-distance migration of vector mosquitoes in  
sub-Saharan Africa, and (i) unmet funding drift.
3.1  Gene deletions compromising performance of Rapid Diagnostic Test (RDT) 
Kits
Rapid diagnostic tests (RDTs) detect species-specific antigens of P. falciparum 
and P. vivax parasites present in the blood of infected patients. Histidine rich 
protein 2 and 3 (Pfhrp2, Pfhrp3) are widely used in RDTs for point-of-care diagnosis 
of P. falciparum. Naturally occurring deletions of these genes are emerging threat to 
malaria detection and treatment, management and elimination. Pfhrp2/3 deletions 
are increasingly reported from all malaria-endemic regions. Deletion of Pfhrp2/3 
genes in P. falciparum is one of the major issues for diagnosis of this dominant 
species globally. A recent detailed global review by WHO clearly showed a huge 
problem exists in Amazon basin and Eritrea [8, 9].
In India, two major studies reported the problem is limited to 0 to 23%  
[10, 11]. The global distribution and prevalence of these deficient genes is 
presented in Figures 3 and 4. In the Peruvian Amazon, there was emergence of 
a drug-resistance profile BV1 clonal lineage that was distinctly different from 
the previous genotype found in the region [12]. The BV1 lineage profile posed a 
significant problem because the strain is multidrug-resistant and escapes detec-
tion by Pfhrp2-based RDTs secondary to Pfhrp2/3 deletions. The hypothesis was 
that the BV1 strain had emerged as a successful parasite lineage for transmission 
by different vectors and had contributed to the increased malaria burden recently 
observed in some Amazonian regions [13].
As per the report of WHO, of the 39 reports published in 39 countries, 32 (82%) 
reported Pfhrp2 deletions. However, deletions are still unclear when variable 
methods in sample selection and laboratory analysis are performed. From the 16 
published documents in 15 countries between 2019 and September 2020, Pfhrp2/3 
deletions were confirmed in 11 countries from 12 reports. These countries are 
China, Equatorial Guinea, Ethiopia, Ghana, Myanmar, Nigeria, Sudan, Uganda, 
United Kingdom (imported malaria cases from various malaria endemic countries), 
the United Republic of Tanzania and Zambia. However, no deletions were detected 
in France (among returning travelers), Haiti, Kenya and Mozambique [5].
Current Topics and Emerging Issues in Malaria Elimination
4
3.2 Drug resistance
The WHO recognises that drug resistance is one of the main concerns which 
requires periodic monitoring and appropriate drug policy in place to stay a step 
ahead arresting development and spread of drug-resistant malaria. In recent years, 
molecular monitoring and surveillance of mutant markers has gained pace to help 
the programme significantly providing an early indication of possible drug failure 
helping institutes alternated therapeutic regimen for radical cure [14]. P. falciparum 
and P. vivax are the two common human malaria parasite species, of which the 
former is widespread and continually evolving to be drug-resistant (Figure 5).
3.2.1 Plasmodium falciparum
Among all human malaria parasite species, P. falciparum is the most dominant 
species especially in sub-Saharan Africa. Recent first high-resolution global map of 
Figure 3. 
Highest percentage of Pfhrp2 deletions in P. falciparum cases tested. Source: WHO [8] and Thompson et al. [9].
Figure 4. 
Weighted average estimates for Pfhrp2 deletions in P. falciparum patients tested by country. Source: WHO [8] 
and Thompson et al. [9].
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falciparum mortality, prevalence and incidence illustrated a rapid decline in burden 
between 2005 and 2017. However, 90.1% of people continue to reside within sub-
Saharan Africa which accounted for 79.4% of cases and 87.6% of deaths in 2017 [15].
Besides in-vivo follow-up studies for monitoring therapeutic efficacy, the 
Technical Consultation Committee of WHO recommended the use of malaria 
molecular surveillance (MMS) for implementation in malaria elimination and con-
trol. Monitoring of molecular marker and therapeutic efficacy studies help to identify 
and track the prevalence of molecular mutations associated with drug resistance.
3.2.1.1 Chloroquine resistance markers
Once Chloroquine was a first-line drug for malaria treatment but has become 
obsolete for treatment of P. falciparum. Chloroquine-resistant falciparum malaria 
first reported in Thailand in 1957 (Figure 5). Subsequently, it spread through South 
and Southeast Asia and by the 1970s in sub-Saharan Africa and South America 
[16]. In India, predominant SVMNT haplotype of PfCRT K76Tmutation was first 
reported in 2004 [17]. Presence of SVMNT haplotype rather than CVIET specific 
of the African/Southeast Asian haplotype in India was suggestive of prevalence of 
chloroquine resistance in Indian strains of P. falciparum [17]. This helped replacing 
chloroquine as first-line drug for P. falciparum malaria to artemisinin-based com-
bination therapy (ACT). But a study in 2020 in Mizoram (bordering Myanmar), 
reported prevalence of CVIET haplotype indicating its presence in this region of 
India [18]. Molecular surveillance of markers has helped trace the route of migra-
tion of drug-resistant malaria in the world (Figure 5).
3.2.1.2 Sulfadoxine-Pyrimethamine (SP) resistance markers
Dihydropteroate synthase (dhps) inhibitors, such as sulfadoxine, and dihydro-
folate reductase (dhfr) inhibitors, such as pyrimethamine, disrupt parasite′s folate 
synthesis. Antifolate resistance has been associated with point mutations in the 
pfdhps and pfdhfr genes. Point mutations at codons 16, 51, 59, 108 and 164 of pfdhfr 
inhibit its activity, and the parasite becomes resistant to pyrimethamine. Two 
mutations C59R and S108N in pfdhfr were recorded to be prevalent in India. While 
mutations at 436, 437, 540, 580 and 613 of pfdhps reduce the substrate binding 
capacity and confer resistance to sulfadoxine. Three mutations S436A, A437G and 
K540E were found associated with pfdhps [19].
Figure 5. 
History of Chloroquine-resistant P. falciparum malaria. Origin of resistance in 1957 from South East Asia and 
global spread in subsequent years. Source: Packard [16].
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Intermittent preventive treatment in pregnant women (IPTp) and in infants 
(IPTi) sulfadoxine-pyrimethamine (SP) is recommended to prevent P. falciparum 
malaria in moderate to high transmission areas of sub-Saharan Africa. But the 
major problem lies on resistance of SP to P. falciparum. As per WHO protocol, SP is 
no more effective for IPTp and IPTi in most of eastern Africa and parts of central 
Africa. WHO recommends countries to withdraw IPTp when the prevalence of 
pfdhps 540E is >95% and pfdhps 581G >10%, and ITPi when the prevalence of pfdhps 
540E is >50% [20]. However, a recent meta-analysis found that IPTp still reduces 
the risk of low birth weight even in areas where high level of pfdhps and pfdhfr 
quintuple mutant haplotypes are present. But in areas where the sextuple mutant 
parasite harbouring the additional pfdhps 581G mutation ITPi appears to have no 
significant protective effect. Therapeutic alternatives to SP-IPTp are needed in areas 
where the prevalence of the sextuple mutant parasite exceeds 37% [21].
3.2.1.3 Artemisinin resistance marker
Artemisinin-based combination therapy (ACT) is presently the drug of choice 
for treatment of resistant P. falciparum malaria. Mutation at Pfkelch13 propeller 
gene (K13) responsible for its role in Artemisinin resistance supposedly originated 
in Southeast Asia [22]. WHO has prepared a list of validated PfKelch13 mutations 
of partial resistance to artemisinin. These are F446I, N458Y, M476I, Y493H, R539T, 
I543T, P553L, R561H, P574L and C580Y, and also the candidate markers P441L, 
G449A, C469F/Y, A481V, R515K, P527H, N537I/D, G538V, V568G, R622I and A675V 
[5]. A recent review in the NEJM, a worldwide map of K13-propeller polymorphism 
found no evidence of Artemisinin resistance outside Southeast Asia and China, 
where resistance-associated Pfkelch13 mutations were confined [23]. Later, after 
comparing the Pfkelch13 R561H genome sequence to other samples taken from 
all over Africa, and sequences taken from South America and Bangladesh, it was 
observed that the artemisinin-resistant strain of the parasite is tightly clustered 
with Rwandan parasites indicating artemisinin resistance in Africa [24].
In 2019, a report from eastern India indicated the presence of two mutations 
G625R and R539T in 5/72 P. falciparum cases treated with artemisinin that linked 
to its presence of resistance [25]. But C580Y in kelch13 in Southeast Asia and 
Mekong Delta areas were predominant [26]. Following high rates of Artesunate 
(AS) + Sulfadoxine-Pyremethamine (SP) treatment failure in the north-eastern 
provinces in 2013, India changed its treatment policy in those provinces to 
Artesunate-Lumefantrine (AL); while AS+SP remains effective elsewhere in the 
country [5]. Moreover, a specific lineage of plasmepsin amplification (PLA1) has 
been detected that caused dihydroartesunate-piperquine (DHA-PPQ ) treatment 
failure in western Cambodia due to its use as mass drug administration campaign 
[5]. Both the lineages of k13 (KEL1) and PLA1 have compounded the problem of 
DHA-PPQ resistance in this region [13]. In Guyana, between 2010 and 2017, the 
C580Y mutation also emerged independently. However, recent studies indicated 
100% of samples were found to be wild type, indicating that the mutation may be 
disappearing in Guyana. There is no indication of lumefantrine failure in Africa [5].
3.2.2 Plasmodium vivax
P. vivax was believed to be a benign malaria, but this phenomenon has changed 
in recent years for its appreciable causes of morbidity and mortality [27]. In recent 
years, this species has amounted to cause a significant public health burden [28, 29]. 
Even though there has been a considerable decrease on the burden, still over four 
billion people are living at risk of this infection. In 2017, vivax transmission was 
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reported from 49 countries across Central and South America, the Horn of Africa, 
Asia, and the Pacific islands. P. vivax is the predominant species in almost two-
thirds of co-endemic countries. Recent estimates, incorporating national surveil-
lance data, prevalence surveys, and geospatial mapping, have revised the global 
burden to between 13.7 and 15 million cases in 2017 [30, 31]. It is assumed that ACT 
is widely used across Africa to combat falciparum malaria that may be favouring 
adaptive selection for P. vivax for its failure. Additionally, a better understanding 
is needed on the mechanism of erythrocytes invasion in Duffy-negative individu-
als who were previously thought to be protected against P. vivax malaria [32]. An 
estimated 82% (11.7 million cases) of the global vivax burden comes from four 
high-burden countries, i.e. India, Pakistan, Ethiopia, and Sudan [33].
In most countries, chloroquine is still being used for the treatment of blood 
stages of P. vivax malaria. However, chloroquine-resistant (CQR) P. vivax has 
emerged in many areas with variable degree of clinical efficacy [34]. High-grade 
chloroquine resistance is reported from the intense transmission area of the island 
of Papua (Indonesia and Papua New Guinea), and Sabah (Malaysia) where malaria 
elimination is well within reach [33]. To combat the declining susceptibility of P. 
vivax to chloroquine, five countries that include Indonesia, Papua New Guinea, 
Solomon Islands, Vanuatu and Cambodia have adopted a policy of universal ACT 
for both P. falciparum and P. vivax [33]. In other areas where CQR is low-grade and 
transient, chloroquine remains the main drug of choice for treatment of P. vivax 
malaria including four high-burden countries [33, 34].
Molecular monitoring of chloroquine resistance in P. vivax is an integral part 
of national malaria control programme. The P. vivax ortholog of pfcrt, referred as 
pvcrt-o, was characterized nearly two decades ago [35]. A lysine (AAG) insertion 
at amino acid 765 position 10 (K10) was discovered in Southeast Asian strains and 
suggested to be associated with chloroquine resistance where high dose of chloro-
quine is recommended [36].
In India, chloroquine is still effective for treating P. vivax malaria. Almost half 
of the malaria cases are due to P. vivax mostly present in low transmission settings 
[28]. A study in 2013 in Kolkata by Ganguly et al. observed non-synonymous 
polymorphism in pvcrt-o and pvmdr1 and concluded no indication of chloroquine 
resistance in in vivo study [37]. But the report in 2018 from Mangalore indicated 
the presence of chloroquine resistance involving two genes in K10 insertion in 
pvcrt-o and F1076L mutations in pvmdr1 [38]. Subsequently, such mutants were 
also detected in Puducherry, Mangaluru (Mangalore), Cuttack and Jodhpur [39]. 
A study in Chandigarh, North India reported double mutations in K10 insertions 
at 17.5% and 9.5%, in complicated and uncomplicated P vivax groups, respectively. 
Pvmdr-1 gene analysis revealed 100% double mutants (T958M/F1076L) in the 
complicated, and 98.7% in the uncomplicated group, respectively. Presence of a 
single triple mutant T958M, F1076L and Y1028C was observed in the uncomplicated 
group [40]. More number of such cases were reported from Peru in amino acid 
changes at positions 976F and 1076 L for pvmdr1 [41], Afghanistan [42], Malaysia 
[43], Australia (among travellers) [44] and Brazilian Amazon [45].
Tackling P. vivax malaria is a herculean task due to its complex biology of 
hypnozoites that cause relapse. Primaquine – an 8 aminoquinoline is widely used 
for radical cure of malaria. But its use has been restricted in infants, pregnant 
women and also in G6PD-deficient individuals. WHO recommends to administer 
primaquine for radical cure of vivax relapse. More than 180 different G6PD defi-
ciency alleles reported [5]. Cytochrome P450 2D6 is an enzyme that in humans is 
encoded by the CYP2D6 gene. CYP2D6 is primarily expressed in the liver, and is 
associated with primaquine tolerance [46]. So, both G6PD deficiency and CYP2D6 
are contraindications to primaquine administration. In certain situations, high-dose 
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primaquine regiments are currently recommended for radical cure of vivax malaria 
in Southeast Asia and Oceania [47].
Mutations at the pvdhps and pvdhfr loci leading to antifolate resistance are 
commonly found in P. vivax isolates from P. vivax-infested areas. DHFR mutations 
in Plasmodium vivax in Indonesia failed to therapeutic response to SP [48]. Triple 
mutations in pvdhfr was reported in Mangalore, India [49]. Thus, antifolates are not 
currently recommended as a first-line treatment of vivax malaria [50].
4. Invasiveness of Anopheles stephensi
Anopheles stephensi was originally described by Liston in 1901 from a village 
Ellichpur (now Achalpur) in Amravati district, Maharashtra state of India. This 
species is a principal malaria vector in urban India, and is considered imminent 
threat to malaria elimination efforts [51]. This species has three variants i.e. type, 
intermediate and mysorensis based on its egg morphometric analysis. Both type and 
intermediate forms are efficient vectors in rural and urban settings, but type form 
is the main and very efficient vector in urban settings, whereas variety mysorensis is 
considered as a rural vector with limited role. Laboratory studies have shown that 
all the three variants are capable of harbouring rodent malaria P. berghei [52] and 
P. yoelii nigeriensis [53] parasites respectively. An. stephensi is an efficient vector for 
transmitting P. falciparum and P. vivax malaria equally in the field [54].
Recent reports indicate that An. stephensi is expanding its geographical range 
crossing from the Arabian Gulf into the Horn of Africa where it has been reported 
in Djibouti City in 2012 [55], in Ethiopia in 2016 [56] and the Republic of Sudan 
[57]. In 2016, type form of this species was found for the first time in Sri Lanka [58]. 
Emergence of An. stephensi has been associated epidemiologically with an unusual 
resurgence in local malaria cases in Djibouti city [55]. This species is basically a 
container breeder and sympatric co-share breeding with Aedes aegypti [59]. In Sri 
Lanka, An. stephensi has been found to breed in salt water [58]; while it breeds in 
clear water in central regions of urban setting of Africa, but with all probability it 
Figure 6. 
The new “out of range” occurrence of An. stephensi in the Arabian Peninsula and Horn of Africa showing the 
358 An. stephensi site locations used in final species distribution models (SDMs) colour coded by the decade in 
which they were sampled. Source: Sinka et al. [61] with permission.
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may even breed in polluted water in Africa where most malaria vectors breed in such 
waters [60]. Sinka et al. prepared evidence-based maps predicting the possible loca-
tions of An. stephensi across Africa where it could establish if its spread is unchecked. 
The high probability maps predict the presence of An. stephensi in many urban cities 
across Africa where an estimated over 126 million people live (Figure 6) [61].
5. Long-distance travel of mosquitoes
Transportation of mosquitoes from one place to other through surface trans-
portation or air route is well known. The accidental invasion of An. gambiae in 
1930 in Natal, Northeast Brazil from Dakar, Senegal most likely adult mosquitoes 
that travelled in planes or ships, as no larvae were found is one such example [62]. 
Generally, mosquitoes can fly within a few kilometers from their breeding habitats. 
But long-distance migration across hundreds of kilometers during night hours is 
very revealing, and have implications in malaria eradication efforts. Recent study in 
Sahel desert of Mali in Africa, Huestis et al. reported that mosquitoes could possibly 
migrate up to 300 kilometers for 9-hour flight duration. Sticky nets tethered to 
helium-filled balloons fixed in the study villages suspended at set altitudes ranging 
from 40 to 290 metres above mean sea level were launched at about 10 consecutive 
nights each month over a span of 22–32 months. Ten species, including the primary 
malaria vector An. coluzzii, were identified among 235 Anopheline mosquitoes that 
were captured during 617 nocturnal aerial collections. Annually, the estimated 
number of mosquitoes that possibly could have migrated at altitude that cross 
a 100-km line perpendicular to the prevailing wind direction included 81,000 
Anopheles gambiae ss, 6 million An. coluzzii and 44 million An. squamosus. Females 
accounted for more than 80% of all of the mosquitoes, and 90% of them had taken 
a blood meal before their migration, and studies suggest mosquito infection rates 
in the region are between 0.1% and 5% [63, 64]. Annually, the estimated numbers 
of mosquitoes at altitude that cross a 100-km line perpendicular to the prevailing 
wind direction. The authors concluded that millions of malaria vectors that have 
previously fed on blood may migrate frequently over hundreds of kilometers, and 
spread malaria [64]. Thus the successful elimination of malaria depends on how the 
sources of migrant vectors can be identified and controlled.
6. Insecticide resistance
Resistance to insecticides in vector mosquitoes is an organic de novo biological 
process. This has caused a major setback in achieving malaria elimination. Recently 
an update at global scale on insecticide resistance in malaria vectors has been 
enumerated [65]. WHO documented a cumulative total of 82 countries reported 
data on insecticide resistance from 2010 through 2019. Resistance of malaria vectors 
to insecticides threatens malaria control and elimination efforts. Commonly used 
insecticides are synthetic pyrethroids, organophosphates, carbamates and the rarely 
used organochlorine dichlorodiphenyltrichloroethane (DDT) [5].
Sources of insecticides in the environment include the application of insecticide-
based vector control interventions for public health such as Indoor Residual Spray 
(IRS) and the application of agricultural insecticides, which include the same class of 
insecticide as those used in vector control programme [66]. Also pesticide contamina-
tion in water bodies is also a cause of selection pressure for resistance in mosquito 
larvae [67]. In response to the Roll back malaria (RBM) initiative, long lasting insec-
ticide nets (LLIN) coverage increased markedly across Africa from 2005 [68], while 
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IRS usage has been restricted in smaller areas [69]. Either permethrin or deltamethrin 
was used initially in insecticide-treated nets (ITNs), and now α-cypermethrin is most 
commonly used in LLINs. Deltamethrin, λ-cyhalothrin, and DDT have been used 
for IRS for over 20 years. In 2003, first α-cypermethrin was used in mass campaigns. 
Deltamethrin has been the sole pyrethroid along with DDT and other non-pyrethroid 
insecticides are used in IRS from 2015 [69]. There are conflicting reports on the cause 
of insecticide resistance in field mosquitoes following the introduction of LLINs, 
IRS or both. Some studies documented an increase in resistance [70]; whereas others 
observed no such evidence after implementation of these intervention strategies [71].
Anopheles culicifacies is the main vector out of six primary malaria vectors and 
responsible for 2/3 malaria cases distributed across rural India. An tempo-spatial 
analysis of insecticide susceptibility status between 1991 and 2016 from 145 dis-
tricts in 21 states indicated resistance to at least one insecticide in 70% (101/145) 
of the districts – mostly to DDT and malathion whereas, its resistant status against 
deltamethrin varied across the districts [72]. Similar trend was also reported in 
Odisha – a highly malaria-endemic state in India [73].
In India, National Vector Borne Disease Control Programme (NVBDCP) has 
distributed about 50 million LLINs to malaria-endemic communities for interven-
tion during 2016–2018, and to 126 million population at risk [74]. The lower efficacy 
of synthetic pyrethroids to vector mosquitoes is a matter of concern. Certain major 
drawbacks of LLINs include feelings of suffocation in humid tropical climate, and 
some traditional practices compelling the users to wash the nets more frequently 
than prescribed protocol. Another risk of using LLINs is host switching and pos-
sible horizontal transmission potential in the endemic areas [73].
Resistance of malaria vectors to pyrethroids may pose a serious problem in 
achieving the malaria elimination goal. The six countries Cambodia, China (Yunnan 
Province), the Lao People’s Democratic Republic (PDR), Myanmar, Thailand and 
Viet Nam of the Greater Mekong Subregion (GMS) have made significant gains in 
their battle to eliminate malaria by 2030. In recent years, there has been a remarkable 
progress towards elimination of the disease. Between 2012 and 2018, the reported 
number of malaria cases fell by 74%; malaria deaths fell by 95% over the same period. 
However, Cambodia contributes almost half of malaria in this zone of which 85% are 
P. vivax. This may be due to high degree resistance of pyrethroids [75] (Figure 7).
Figure 7. 
Resistance of malaria vectors to pyrethroids in the Greater Mekong Subregion, 2010–2019. Source: WHO [75].
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Another important aspect is to understand and track gene flow in Anopheline 
mosquitoes. This is complex given the amount of genetic diversity that exists within 
mosquito populations. Figure 8 depicts a clear picture how comparative genomics 
can be applied to understand differences in vectorial capacity and their impact on 
malaria transmission [13].
7. Poor disease surveillance
Disease surveillance is the key intervention strategy to support malaria 
elimination. A new guideline promulgated by WHO in 2018 reinforced the GTS 
and framework for elimination principle that identified surveillance as the main 
elimination strategy. But poor surveillance continues to derail the elimination 
efforts. Strengthening surveillance system in many countries eliminated malaria 
successfully. Aiming malaria elimination, a standardized surveillance system land-
scaping compared with ideal system were conducted in 16 countries aiming malaria 
elimination. Assessment was done in 2015 and 2016 across the Greater Mekong 
Subregion (Cambodia, Laos, Myanmar, and Vietnam), Southern Africa (Botswana, 
Mozambique, Namibia, South Africa, Swaziland, and Zimbabwe), Hispaniola 
(Dominican Republic and Haiti), and Central America (Costa Rica, Guatemala, 
Honduras, and Panama). This landscaping analysis provided a clear framework 
that identified multiple gaps in current malaria surveillance systems. It is important 
to close these gaps identified which will allow countries to deploy resources more 
efficiently, track progress, and accelerate towards malaria elimination [75]. Rapid 
reporting and information on geolocation have been the strength of malaria control 
system in Zanzibar for over a decade resulting in low transmission of malarial cases 
[76]. However, falciparum malaria remains a problem in Zanzibar and Swaziland 
[77–79]. China adopted and continues the `1-3-7’ surveillance strategy, whereby 
case notification occurs within one day, case investigation within three days and 
foci investigation and targeted action within seven days. To avoid transmission and 
re-establishment, monthly bulletins are issued on reported and detected cases. 
Training, technical support and supervision are provided regularly to sustain capac-
ity [80]. In Mangalore, India a `1-3-7-14’ strategy is under operation using digital 
TAB-based smart surveillance which focuses on real time micromanagement of 
each malaria positive case and vector control operation [81, 82]. Digital surveillance 
Figure 8. 
Comparative genomics of vector mosquitoes to understand difference in vectorial capacity. Source WHO [13].
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and bridging the surveillance gaps are two major issues have been advocated to 
accelerate towards malaria elimination [83].
8. Discussion
In the last five years the GTS milestone has drawn a detailed road-map to 
eliminate malaria from 2016 to 2030. It can be seen from the Table 1 that all the 58 
countries in the Europe and Central Asia territories, and in other territories around 
50% achieved malaria elimination except Sub-Saharan Africa. This means the real 
problem still exists in this territories [83]. This also reflects in the world malaria 
report. In November 2018, WHO together with RBM Partnership to End Malaria 
has launched the ‘high burden to high impact’ (HBHI) approach – a targeted  
malaria response in all 11 high malaria burden countries, and India is one such 
country outside Africa. Figure 9 shows how HBHI countries have initiated high-
level political engagement and support [5]. In a recent virtual meeting of MPAC of 
WHO commended the efforts made so far in the COVID-19 pandemic. Training 
should aim to increase the sub-national capacity for evidence-driven decision-
making and translating those decisions into actions [13].
Over 100 countries have successfully eliminated malaria in the last century. In 
the past two decades a lot of initiatives have been launched to contain and eliminate 
malaria, viz., Roll Back Malaria (RBM), President’s Malaria Initiative (PMI), Asia 
Pacific Malaria Elimination Network (APMEN), E-2020, Malaria Elimination 
Research Alliance (MERA) - India [84, 85]. Many countries have developed national 
elimination goals. Regional networks have been formed to facilitate collaboration 
[86]. Leaders from the Asia Pacific Leaders Malaria Alliance (APLMA) in November 
2014 and the African Leaders Malaria Alliance in January 2015 endorsed regional 
goals for malaria elimination by 2030 [87, 88]. In 2009, the APMEN was established 
initially in 10 countries (Bhutan, China, Democratic People’s Republic of Korea 
(DPR Korea), Indonesia, Malaysia, the Philippines, Republic of Korea, Solomon 
Islands, Sri Lanka, and Vanuatu), and now have expanded to 18 countries add-























46 38 58 23 45 211
1900 2 13 3 1 1 20
1900–1949 0 0 9 0 0 9
1950–1978 23 5 35 4 1 68
1979–1990 0 1 2 2 1 6





29 21 58 14 3 125
Table 1. 
Number of countries and territories that eliminated malaria by region, 1900–2019. Compiled from Shretta et 
al. [84] and WHO [8].
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Nepal, Papua New Guinea, Thailand, and Vietnam. Among these, India contributes 
maximum malaria cases explaining the importance of malaria elimination in this 
country [89]. But China (Yunnan), Cambodia, Thailand, Myanmar, Lao PDR and 
Viet Nam in Greater Mekong Subregion greatly reduced falciparum malaria [85] 
and now the Mekong Malaria Elimination Programme is ready for the last mile of 
malaria elimination [90].
The real malaria burden lies in the sub-Saharan Africa region. There were 
significant impact of malaria control from 2000 to 2015, but the situation has pla-
teaued between 2015 and 2019 largely attributed to emerging synthetic pyrethroid 
(PY) resistance in the principal malaria vector An. gambiae. Adding piperonyl 
butoxide (PBO) enhances the efficacy of PY, but the requirement is huge, and costs 
have risen substantially amidst financial gap. In high insecticide resistance areas, 
pyrethroid-PBO nets increase mosquito mortality and reduce blood feeding rates 
that leads to lower malaria prevalence. But the impact of pyrethroid-PBO LLINs 
on mosquito mortality was not sustained over 20 washes. There is a little evidence 
to support higher entomological efficacy of pyrethroid-PBO nets in areas where 
the mosquitoes show lower levels of resistance to pyrethroids [91]. This warrants 
routine monitoring of insecticide resistance to take appropriate decisions by the 
national programme managers.
In India the total global burden has reduced from 4% in 2018 to 2% in 2019 of 
total malaria cases. But it still falls under the `high burden to high impact’ countries 
outside Africa. India contributed 87.9% of total malaria cases and 86% of malaria 
deaths in the South East Asia region of WHO [5]. This requires a special attention 
for the high burden states with high P. falciparum cases. For example, malaria cases 
in Karnataka state, India fell 98.95% in 2019 compared with 1995 data, but 70 to 
80% of reported cases from Mangalore city alone requires concerted efforts. Now, a 
special action plan with digital surveillance has been initiated for the last five years, 
which is showing some results. Hopefully, Karnataka can declare malaria elimina-
tion by 2025 ahead of India’s deadline of 2027 [81, 82]. Such strong surveillance 
system can be implemented to find a solution to get freedom from malaria.
In recent years many innovative intervention strategies have been shown to 
be promising. Finding the reasons for Pfhrp2/3 deletions and drug resistance in P. 
falciparum is an important step to address this major issue. BV1 lineage is associated 
Figure 9. 
Schematic presentation how ‘High burden to high impact’ countries get back on track to achieve the GTS 2015 
milestone. Source WHO. [5].
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with these two important issues [8]. Moreover use of other more advanced RDT 
like malaria-RDT (mRDT) can be an alternative where deletions Pfhrp2/3 are low 
[92]. However, alternative RDT options based on detection of the Plasmodium 
lactate dehydrogenase [pLDH]) are limited; in particular, there are currently no 
WHO-prequalified non-Pfhrp2 combination tests that can detect and distinguish 
between P. falciparum and P. vivax [5]. In such situation photo-induced electron 
transfer- polymerase chain reaction (PET-PCT) or microPCR devices can be applied 
with highest accuracy at point-of-care. Issue of asymptomatic malaria cases can 
addressed because these devices can detect a very low level of parasitaemia [93, 94].
Besides, burden of asymptomatic parasite cases in most malaria-endemic coun-
tries, molecular monitoring of drug resistance in parasites and insecticide resistance 
in vector populations are two vital parameters which can help make correct policy 
decisions by the national malaria control programmes. Many countries have initi-
ated for molecular surveillance; for example in Haiti [93], in Asia-Pacific countries 
[95] and Cambodia [96]. Genome analysis is not done in most situations due to its 
prohibitive cost. Now very sensitive and low-cost oxford nanopore platform is very 
useful and many researchers are using this to find out the gene flow and genetic 
diversity in parasites and vectors [97]. SNP barcode is used instead of microsatellite 
technology using this platform [98]. Scientists in Africa have been working on these 
issues on Pathogens Genomic Diversity Network Africa [99]. Such platforms must 
work on other regions also to provide guidance to the national malaria programme 
from time to time for taking corrective measures to change the policy decisions. 
Similarly, vector resistance to insecticide pattern can also established to take correct 
selection of effective insecticide [100].
Monitoring of insecticide resistance allows targeting of specific interventions 
with pyrethroid-PBO nets, and resistance mechanisms finding mixed-function 
oxidase (MFO) resistance mechanisms over time. Such monitoring also enables pro-
grammes to assess the value of different insecticide resistance management strate-
gies like IRS rotation, new types of ITNs and LLINs or other effective tools. Using 
genotyping to detect insecticide resistance is quicker to implement than phenotypic 
assays that require rearing of larvae, even wild type adults can be used when avail-
able in sufficient numbers. It is possible that resistance could be underestimated 
due to unknown age of the mosquito. With this approach, shifts in allele frequencies 
may be easier to detect than shifts in phenotype over short time periods [13].
Finding origin of the parasites and gene flow in the elimination era is a chal-
lenging task. Genetic relatedness studies using metrics of identity-by-state (IBS) 
and identical-by-descent (IBD) - alleles that are genetically the same, and alleles 
that come from a common ancestor, respectively can address this issue [101]. This 
requires a number of informative markers (molecular barcode genotyping) that 
vary depending on the level of transmission in the geographic area under examina-
tion. A barcode is considered informative for relatedness by IBS at >0.95 related-
ness. When using this measure in a low transmission setting, relatedness can serve 
as a key indicator for distinguishing imported and local transmission and under-
standing the persistence of transmission in the area [13].
In high falciparum areas an alternative approach to understanding receptivity 
risk for imported and onward indigenous transmission of malaria is to inves-
tigate parasite markers in parasite-vector interactions that determine whether 
the parasite can successfully infect the mosquito. Pfs47 is a target of interest 
allows the ookinete to evade the immune response of the mosquito midgut and 
successfully develop into an oocyst. The allele is polymorphic with signatures of 
natural selection relevant to the geographic origin of the parasite. P. falciparum 
isolates are more compatible with Anopheles species from their region of origin. 
Pfs47 single nucleotide polymorphisms (SNPs) can therefore be used to predict 
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the transmission risk of imported P. falciparum and help establish its geographic 
origin. Specific SNPs for vivax malaria is warranted [13].
Now time has come act judiciously to eliminate malaria at subnational to achieve 
elimination target at national level. Again surveillance that can capture and report 
individual cases in time to investigate and take action [81, 82]. The Chinese national 
malaria elimination programme, now approaching WHO certification used 
effectively in subnational initiatives to interrupt malaria transmission followed by 
validations of elimination [102] Similarly, Kenya has established a national strategic 
action plan 2019–2023 to achieve malaria elimination in targeted countries by 2030 
[103]. Malaysia has successfully launched malaria elimination partnering between 
the public and commercial sectors in Sabah [104], but the rising threat of zoonotic 
P. knowlesi is a matter of concern [105].
Time has come to look back the success stories of malaria elimination efforts. 
In October 1998, the Director-General of WHO launched the RBM initiative. 
It was established through a partnership between WHO, the World Bank, the 
United Nations Children’s Fund (UNICEF) and the United Nations Development 
Programme (UNDP) [106]. The purpose of launching RBM initiative was in this 
direction. In Karnataka, India we successfully implemented larvivorous fish-based 
malaria elimination campaign [107, 108]. We need to repurpose the larval source 
management strategy. The best historical example is the successful eradication of 
accidentally introduced African vector Anopheles gambiae in 54000 km2 of largely 
ideal habitat in Northeast Brazil (Natal) from Dakar, Senegal in the 1930s and early 
1940s. This outstanding success was achieved through an integrated programme but 
relied overwhelmingly upon larval control. The success of Frederick Lowe Soper and 
Rockeller Foundation’s International Health Division campaigned with anti-larval 
chemical Paris Green and eliminated An. gambiae before the scheduled timeline 
[62]. It was a significant watershed in the history of malaria control, and revived the 
faith in vector control strategies that paved the way for the application of eradica-
tion methods in the fight against malaria following World War II. This experience 
was soon repeated in Egypt and another larval control programme successfully 
suppressed malaria for over 20 years around a Zambian copper mine [109]. It is 
important to revisit all such success stories implemented earlier. Today, with the 
development of advanced technology, we have more options like application of a 
new anti-larval product Aquatain AMF™ for use in LSM. It is a silicon-based liquid 
formulation that forms a very thin film on stagnant water. The mosquito larvae are 
killed due to physical and mechanical action. Drone technology are now used for 
anti-larval applications [110]. Rhamnolipids – a class of glycolipid may be applied as 
anti-larval agent especially against Ae. aegypti and may be against A. stephensi [111].
Efforts are also being made to develop technology for diagnosis of malaria 
parasites and identification of vector mosquitoes using artificial intelligence and 
machine learning. [112, 113]. Aptamer technology can be applied which has the 
potential to revolutionize biological diagnostics and therapeutics. This technology 
can be used for malaria diagnosis in place of HRP2 which is facing certain prob-
lems [114, 115]. This also be used in malaria as adjunct therapy [116]. Other most 
prospective gene editing technology in vector mosquitoes especially in An. gambiae 
in Africa where most malaria exists, and also in An. stephensi – the most invasive 
malaria vector. [61, 110, 117]. It is important to find new drug molecules to counter 
drug resistance challenge in parasites. Medicines for Malaria Venture (MMV) has 
been working for more than two decades in this front. P. vivax liver stage assays 
platform was initiated by MMV to discover new molecules for anti-relapse drugs to 
work against hypnozoites. India was one of the partners under this initiative [118]. 
A new vaccine candidate R21 with adjuvant Matrix-MTM developed by Novamax 
has shown a new hope for an effective vaccine that could be used in malaria 
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elimination. A Phase 2B trial on 450 children aged 5-17 months in Burkina Faso, 
West Africa showed 77% efficacy [119].
Now, all resources have been diverted to COVID-19 even WHO alerted in the 
beginning of the pandemic. In a recent article published in Nature emphasized the 
need to create a general attention like COVID-19 to all tropical diseases includ-
ing malaria. The author has expressed concerns about the reversing the impact 
on malaria elimination achieved so far especially in Sub-Saharan Africa [120]. It 
may be mentioned that in March 2020, as the COVID-19 pandemic spread rapidly 
around the globe, WHO convened a cross-partner effort to mitigate the negative 
impact of the corona virus in malaria-affected countries and contribute to the 
COVID-19 response otherwise, much of the progress against malaria was under 
enormous risk, with the potential to wipe out 20 years of malaria gains [120].
Funding in malaria elimination efforts is an important component. Sufficient 
and timely release of allocated funds would ease out many constraints for which 
strict financial management is utmost necessary. The total annual financial 
resources needed were estimated at US$ 4.1 billion in 2016, rising to US$ 6.8 
billion in 2020 to achieve the GTS milestone. An additional funding of US$ 
0.72 billion is estimated to be required annually for global malaria research and 
development (R&D). In 2019, the total funding for malaria control and elimina-
tion in was estimated at US$ 3.0 billion, compared with US$ 2.7 billion in 2018 
and US$ 3.2 billion in 2017. The amount invested in 2019 falls short of the US$ 5.6 
billion estimated to be required globally. In recent years, the funding gap between 
the amount invested and the resources needed has widen dramatically, increasing 
from US$ 1.3 billion in 2017 to US$ 2.3 billion in 2018, and to US$ 2.6 billion in 
2019 [5].
9. Conclusion
In the renewed efforts to eliminate malaria more needs to be done following 
the strategies and technologies adopted by those countries successfully eliminate 
malaria. High burden to high impact countries need special attentions. If these 
countries in Africa and India are free from malaria over 80% of malaria burden 
can be curtailed. There are several roadblocks namely gene deletions in Pfhrp2/3, 
insecticide resistance, drug resistance in P. falciparum and also in P. vivax need to 
be addressed following new technologies like gene editing and Aptamar technolo-
gies. There are many gaps in surveillance for which smart digital surveillance is an 
important strategy that need to be implemented on priority. Artificial intelligence 
and machine learning should find proper place to solve many ongoing prob-
lems of diagnosis and effective implementation, monitoring of the elimination 
programme. Routine malaria molecular surveillance of parasites and vectors at 
subnational and regional levels must be carried out to take correct and appropriate 
measures policy decision makers. As long distance night travel and invasiveness 
of vector mosquitoes have been established or otherwise, LSM must find priority. 
Like COVID-19, other tropical diseases like malaria must be given priority with 
proper funding provisions.
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